Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

Annelieke E. C. A. B. Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, Jolien Tol, Yvonne Kamm, Paul C. de Jong, Marianne A. Jonker, Allert H. Vos, Willem Grootjans, Johannes W. B. de Groot, Sasja F. Mulder, Erik H. J. G. Aarntzen, Winald R. Gerritsen, Carla M. L. van Herpen, Nielka P. van Erp*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)641-648
Number of pages8
JournalTargeted Oncology
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2018

Keywords

  • MTOR INHIBITOR EVEROLIMUS
  • SOLID TUMORS
  • PHASE-I
  • ENDOCRINE MONOTHERAPY
  • MAMMALIAN TARGET
  • PLUS EXEMESTANE
  • EFFICACY
  • SAFETY
  • PET
  • CHEMOTHERAPY

Cite this